Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
CAR-T therapies are continuing to gain traction in autoimmune disease, with a notable new case.
Also, the FDA has withdrawn approval of GSK’s leucovorin for a rare brain disorder tied to autism, closing out an unusual episode shaped in part by political pressure.Continue to STAT+ to read the full story…